Investors
We maintain a transparent, comprehensive dialogue with the financial community about our strategy, outlook, financial data, economic environment, and social impact.
Third Quarter 2025
Third quarter 2025 results were reviewed by management during a live audio webcast with the financial community on October 24, 2025. The presentation was followed by a Q&A session.
Press Releases
November 25, 2025
Press Release: Sanofi and Regeneron’s Dupixent approved as the first targeted medicine in the EU in over a decade for chronic spontaneous urticaria
November 14, 2025
Press Release: Sanofi’s Teizeild recommended for EU approval by the CHMP for patients with stage 2 type 1 diabetes
November 7, 2025
Press Release: ACAAI: Sanofi and Regeneron’s Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review
Upcoming Events
19Nov
2025
2Dec
2025
8th Annual Evercore Healthcare Conference with Paul Hudson
11:30 - 12:35 ET | (Coral Gables, FL)
Conferences
3Dec
2025
Citi’s 2025 Global Healthcare Conference with Paul Hudson
03:15 - 03:55 ET | (Miami, FL)
Conferences
30th Consecutive Year of Dividend Increase
Environment, Social, Governance
As a global pharmaceutical company, we stretch everyday to deliver safe and sustainable innovation and play our part in addressing some of the world’s most pressing challenges.
Contact Our Investor Relations Team
For general inquiries
Please contact the switchboard, +33 (0)1 53 77 40 00